Identification of an effector protein and gain-of-function mutants that activate Pfmrk, a malarial cyclin-dependent protein kinase

Molecular and Biochemical Parasitology

Volumn 149, Issue 1, 2006, Pages 48-57

  Chen, Yueqin ^a   Jirage, Dayadevi ^a   Caridha, Diana ^a   Kathcart, April K ^a   Cortes, Edison A ^a   Dennull, Richard A ^a   Geyer, Jeanne A ^a   Prigge, Sean T ^b   Waters, Norman C ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

CDK; Cell cycle; Inhibitor; Kinase; Malaria; MAT1; Pfmrk; PfPK5; Plasmodium falciparum

Indexed keywords

AMINO ACID; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE ACTIVATING KINASE; CYCLINE; ENZYME; MENAGE A TRIOS 1 PROTEIN; MO15 RELATED KINASE; PROTEIN; PROTEIN KINASE 5; RNA POLYMERASE II; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; ENZYME ACTIVATION; ENZYME ACTIVITY; MALARIA; MUTANT; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BINDING SITES; CYCLIN-DEPENDENT KINASES; CYCLINS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS; PHOSPHORYLATION; PLASMODIUM FALCIPARUM; PROTEIN KINASES; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS;

PLASMODIUM FALCIPARUM;

EID: 33745872589     PISSN: 01666851     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molbiopara.2006.04.004     Document Type: Article

References (68)

1. Breman J.G. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 64 (2001) 1-11
2. Winstanley P.A., Ward S.A., and Snow R.W. Clinical status and implications of antimalarial drug resistance. Microbes Infect 4 (2002) 157-164
3. Olliaro P. Drug resistance hampers our capacity to roll back malaria. Clin Infect Dis 41 Suppl. 4 (2005) S247-S257
4. Keenan S.M., Geyer J.A., Welsh W.J., Prigge S.T., and Waters N.C. Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors. Comb Chem High Throughput Screen 8 (2005) 27-38
5. Leete T.H., and Rubin H. Malaria and the cell cycle. Parasitol today 12 (1996) 442-444
6. Arnot D.E., and Gull K. The plasmodium cell-cycle: facts and questions. Ann Trop Med Parasitol 92 (1998) 361-365
7. Doerig C., Chakrabarti D., Kappes B., and Mathews K. The cell cycle in protozoan parasites. In: Armelle J., Bernard D., and Laurent M. (Eds). Progress in Cell Cycle Research vol. 4 (2000), Kluwer Academic
8. Morgan D.O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13 (1997) 261-291
9. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13 (1999) 1501-1512
10. O'Hare M., Wang F., and Park D.S. Cyclin-dependent kinases as potential targets to improve stroke outcome. Pharmacol Ther 93 (2002) 135-143
11. Schang L.M. Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother 50 (2002) 779-792
12. Senderowicz A.M. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 15 (2001) 1-9
13. Ivorra C., Samyn H., Edo M.D., et al. Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease. Curr Pharm Biotechnol 4 (2003) 21-37
14. Morgan D.O. Principles of CDK regulation. Nature 374 (1995) 131-134
15. Morgan D.O. The dynamics of cyclin dependent kinase structure. Curr Opin Cell Biol 8 (1996) 767-772
16. De Bondt H.L., Rosenblatt J., Jancarik J., Jones H.D., Morgan D.O., and Kim S.H. Crystal structure of cyclin-dependent kinase 2. Nature 363 (1993) 595-602
17. Jeffrey P.D., Russo A.A., Polyak K., et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376 (1995) 313-320
18. Russo A.A., Jeffrey P.D., and Pavletich N.P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol 3 (1996) 696-700
19. Doerig C., Endicott J., and Chakrabarti D. Cyclin-dependent kinase homologues of Plasmodium falciparum. Int J Parasitol 32 (2002) 1575-1585
20. Graeser R., Wernli B., Franklin R.M., and Kappes B. Plasmodium falciparum protein kinase 5 and the malarial nuclear division cycles. Mol Biochem Parasitol 82 (1996) 37-49
21. Graeser R., Franklin R.M., and Kappes B. Mechanisms of activation of the cdc2-related kinase PfPK5 from Plasmodium falciparum. Mol Biochem Parasitol 79 (1996) 125-127
22. Merckx A., Le Roch K., Nivez M.P., et al. Identification and initial characterization of three novel cyclin-related proteins of the human malaria parasite Plasmodium falciparum. J Biol Chem 278 (2003) 39839-39850
23. Li Z., Le Roch K., Geyer J.A., et al. Influence of human p16(INK4) and p21(CIP1) on the in vitro activity of recombinant Plasmodium falciparum cyclin-dependent protein kinases. Biochem Biophys Res Commun 288 (2001) 1207-1211
24. Li J.L., Robson K.J., Chen J.L., Targett G.A., and Baker D.A. Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization. Eur J Biochem 241 (1996) 805-813
25. Fesquet D., Labbe J.C., Derancourt J., et al. The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. EMBO J 12 (1993) 3111-3121
26. Poon R.Y., Yamashita K., Adamczewski J.P., Hunt T., and Shuttleworth J. The cdc2-related protein p40MO15 is the catalytic subunit of a protein kinase that can activate p33cdk2 and p34cdc2. EMBO J 12 (1993) 3123-3132
27. Makela T.P., Tassan J.P., Nigg E.A., Frutiger S., Hughes G.J., and Weinberg R.A. A cyclin associated with the CDK-activating kinase MO15. Nature 371 (1994) 254-257
28. Fisher R.P., and Morgan D.O. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 78 (1994) 713-724
29. Nigg E.A. Cyclin-dependent kinase 7: at the cross-roads of transcription DNA repair and cell cycle control?. Curr Opin Cell Biol 8 (1996) 312-317
30. Shuttleworth J. The regulation and functions of cdk7. Prog Cell Cycle Res 1 (1995) 229-240
31. Yankulov K.Y., and Bentley D.L. Regulation of CDK7 substrate specificity by MAT1 and TFIIH. EMBO J 16 (1997) 1638-1646
32. Adamczewski J.P., Rossignol M., Tassan J.P., Nigg E.A., Moncollin V., and Egly J.M. MAT1, cdk7 and cyclin H form a kinase complex which is UV light-sensitive upon association with TFIIH. EMBO J 15 (1996) 1877-1884
33. Rossignol M., Kolb-Cheynel I., and Egly J.M. Substrate specificity of the cdk-activating kinase (CAK) is altered upon association with TFIIH. EMBO J 16 (1997) 1628-1637
34. Larochelle S., Chen J., Knights R., et al. T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity. EMBO J 20 (2001) 3749-3759
35. Fisher R.P., Jin P., Chamberlin H.M., and Morgan D.O. Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase. Cell 83 (1995) 47-57
36. Martinez A.M., Afshar M., Martin F., Cavadore J.C., Labbe J.C., and Doree M. Dual phosphorylation of the T-loop in cdk7: its role in controlling cyclin H binding and CAK activity. EMBO J 16 (1997) 343-354
37. Devault A., Martinez A.M., Fesquet D., et al. MAT1 ('menage a trois') a new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish and Xenopus CAK. EMBO J 14 (1995) 5027-5036
38. Tassan J.P., Jaquenoud M., Fry A.M., Frutiger S., Hughes G.J., and Nigg E.A. In vitro assembly of a functional human CDK7-cyclin H complex requires MAT1, a novel 36 kDa RING finger protein. EMBO J 14 (1995) 5608-5617
39. Waters N.C., Woodard C.L., and Prigge S.T. Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum. Mol Biochem Parasitol 107 (2000) 45-55
40. Le Roch K., Sestier C., Dorin D., et al. Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H Functional characterization of a P. falciparum cyclin homologue. J Biol Chem 275 (2000) 8952-8958
41. Geyer J.A., Prigge S.T., and Waters N.C. Targeting malaria with specific CDK inhibitors. Biochim Biophys Acta 1754 (2005) 160-170
42. Bhattacharjee A.K., Geyer J.A., Woodard C.L., et al. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors. J Med Chem 47 (2004) 5418-5426
43. Woodard C.L., Li Z., Kathcart A.K., et al. Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases. J Med Chem 46 (2003) 3877-3882
44. Marti-Renom M.A., Stuart A.C., Fiser A., Sanchez R., Melo F., and Sali A. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 29 (2000) 291-325
45. Lolli G., Lowe E.D., Brown N.R., and Johnson L.N. The crystal structure of human CDK7 and its protein recognition properties. Structure (Camb) 12 (2004) 2067-2079
46. Nicholls A., Sharp K.A., and Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11 (1991) 281-296
47. Freemont P.S. The RING finger. A novel protein sequence motif related to the zinc finger. Ann N Y Acad Sci 684 (1993) 174-192
48. Honma T., Hayashi K., Aoyama T., et al. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem 44 (2001) 4615-4627
49. Honma T., Yoshizumi T., Hashimoto N., et al. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J Med Chem 44 (2001) 4628-4640
50. Waters N.C., and Geyer J.A. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development. Expert Opin Ther Targets 7 (2003) 7-17
51. Peng Y., Keenan S.M., and Welsh W.J. Structural model of the plasmodium CDK, Pfmrk, a novel target for malaria therapeutics. J Mol Graph Model 24 (2005) 72-80
52. Stiller J.W., and Hall B.D. Evolution of the RNA polymerase II C-terminal domain. Proc Natl Acad Sci USA 99 (2002) 6091-6096
53. Fisher R.P. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 118 (2005) 5171-5180
54. Levine K., Kiang L., Jacobson M.D., Fisher R.P., and Cross F.R. Directed evolution to bypass cyclin requirements for the Cdc28p cyclin-dependent kinase. Mol Cell 4 (1999) 353-363
55. Bell M., Capone R., Pashtan I., Levitzki A., and Engelberg D. Isolation of hyperactive mutants of the MAPK p38/Hog1 that are independent of MAPK kinase activation. J Biol Chem 276 (2001) 25351-25358
56. Diskin R., Askari N., Capone R., Engelberg D., and Livnah O. Active mutants of the human p38alpha mitogen-activated protein kinase. J Biol Chem 279 (2004) 47040-47049
57. Johnson L.N., Noble M.E., and Owen D.J. Active and inactive protein kinases: structural basis for regulation. Cell 85 (1996) 149-158
58. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
59. Kannan N., and Neuwald A.F. Evolutionary constraints associated with functional specificity of the CMGC protein kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2alpha. Protein Sci 13 (2004) 2059-2077
60. Lew J. MAP kinases and CDKs: kinetic basis for catalytic activation. Biochemistry 42 (2003) 849-856
61. Wong L., Jennings P.A., and Adams J.A. Communication pathways between the nucleotide pocket and distal regulatory sites in protein kinases. Acc Chem Res 37 (2004) 304-311
62. Ward P., Equinet L., Packer J., and Doerig C. Protein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryote. BMC Genomics 5 (2004) 79
63. Guo Z., and Stiller J.W. Comparative genomics of cyclin-dependent kinases suggest co-evolution of the RNAP II C-terminal domain and CTD-directed CDKs. BMC Genomics 5 (2004) 69
64. Liu J., and Kipreos E.T. Evolution of cyclin-dependent kinases (CDKs) and CDK-activating kinases (CAKs): differential conservation of CAKs in yeast and metazoa. Mol Biol Evol 17 (2000) 1061-1074
65. Larochelle S., Pandur J., Fisher R.P., Salz H.K., and Suter B. Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity. Genes Dev 12 (1998) 370-381
66. Inamoto S., Segil N., Pan Z.Q., Kimura M., and Roeder R.G. The cyclin-dependent kinase-activating kinase (CAK) assembly factor, MAT1, targets and enhances CAK activity on the POU domains of octamer transcription factors. J Biol Chem 272 (1997) 29852-29858
67. Ko L.J., Shieh S.Y., Chen X., et al. p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol Cell Biol 17 (1997) 7220-7229
68. Bozdech Z., Llinas M., Pulliam B.L., Wong E.D., Zhu J., and DeRisi J.L. The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol 1 (2003) E5